NeuroPhage adds $10M to its Series D to bring brain plaque-clearing Alzheimer’s drug to clinic
Cambridge-based NeuroPhage is developing, well, a better way to clear the trash. It’s chasing Alzheimer’s, Parkinson’s and other aging-related degenerative diseases with a technology that breaks up disease-causing plaques in the brain. The company just tacked on another $10 million to its existing Series D private equity financing, bringing that total round to $27 million. To date, NeuroPhage has […]